ArticleInvestigational new drugs2021

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.

J Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.